ORYZON Receives $1.5 million grant from Alzheimer’s Drug Discovery Foundation (ADDF)
MADRID, SPAIN and CAMBRIDGE MA.
• Proceeds to help fund ETHERAL-US Phase IIa examing vafidemstat in Alzheimer’s disease
• ADDF stake in the company represents 0.94 % of the common stock
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Board of Directors of the Alzheimer’s Drug Discovery Foundation (ADDF) has approved a grant of $1.5 million to Oryzon Genomics S.A. to support the US-arm of Oryzon’s ETHERAL Phase IIa clinical trial with vafidemstat in Alzheimer’s disease (AD) patients.